Loading patent…
AssigneeAmerican Cyanamid Company
InventorsKiran M. Khandke, John Gotto, Ursula Eul
Estimating the term…
Chondroitinase II, a protein having an isoelectric point of approximately 8.4-8.45 and an apparent molecular mass of 112 kDa when electrophoresed in a 4 to 20% gradient acrylamide gel in 25 mM Tris/192 mM glycine buffer at pH 8.5 in the presence of about 0.1% (w/v) SDS, has been isolated and purified. A process for the copurification by affinity chromatography of the chondroitinase I and chondroitinase II proteins produced by Proteus vulgaris is also provided. The proteins can be further purified by metal chelating chromatography. Therapeutic or surgical compositions of isolated chondroitinases I and II or the copurified mixture of chondroitinase I and II are also disclosed. These compositions are used in a method for selectively and completely disinserting the vitreous body from the neural retina of an eye.
A method for selectively and completely disinserting the vitreous body from the neural retina of a human eye, said method comprising administering to an eye in need of such treatment, a disinsertion effective amount of a surgical composition consisting essentially of a mixture of Proteus vulgaris chondroitinase I and Proteus vulagaris chondroitinase II, wherein said composition is essentially free of proteolytic degradation products of said chondroitinase I and chondroitinase II.
A method for selectively and completely disinserting the ocular vitreous body from the neural retina of a human eye, which comprises administering to the eye an effective amount of a composition comprising an isolated and purified chondroitinase II protein having the amino-terminal amino acid sequence corresponding SEQ ID NO:2 and an isoelectric point of approximately 8.4-8.45, and an isolated and purified Proteus vulgaris chondroitinase I protein having an amino-terminal amino acid sequence corresponding to SEQ ID NO:
Dependencies are inferred from the claim text.